对复苏后心肌功能障碍的抗费洛普托特疗法进行主动和被动向治疗
Tao Jin1,2,3,4, Ningjun Chen1, Yuan Cheng1,3
1School of Materials Science and Engineering, Southwest Jiaotong University, Chengdu, Sichuan Province 610031, China.
iScience
|August 18, 2025
概括
一种新的药物输送系统向心脏细胞以抑制铁亡,改善心脏骤停后的结果. 这种纳米粒子系统为复苏后心肌功能障碍提供了有前途的紧急治疗方法.
科学领域:
- 心血管研究研究心血管研究
- 纳米医学是一种纳米医学.
- 细胞生物学 细胞生物学
背景情况:
- 复苏后心肌功能障碍 (PRMD) 是心脏骤停后死亡的主要原因.
- 铁,一种受调节的细胞死亡形式,在PRMD中起着关键作用.
- 目前的铁死抑制剂,如铁素-1 (Fer-1) 的临床适用性有限.
研究的目的:
- 为PRMD治疗开发一种反应性氧物种 (ROS) 响应和心肌向的药物输送系统.
- 评估纳米颗粒 (NP) 封装铁抑制剂 (Fer-1) 在心脏骤停模型中的疗效.
主要方法:
- 工程化ROS响应,心肌向的纳米粒子 (APTD@Fer-1NP) 封装Fer-1.
- 在实验室对H9c2细胞进行测试,以评估抑制低氧再氧化诱导的铁亡.
- 在小鼠心脏骤停模型中的体内研究来评估PRMD,氧化应激,炎症,心脏重塑和生存.
主要成果:
- APTD@Fer-1 NPs表现出良好的生物相容性,并有效抑制H9c2细胞中的ferroptosis.
- 在大鼠中,APTD@Fer-1 NP显著改善PRMD,减少氧化应激和炎症,并减轻心脏重塑.
- 用APTD@Fer-1NP治疗导致复苏后的生存预后得到改善.
结论:
- 开发的APTD@Fer-1NP代表了重症监护机构的可行药物输送策略,使PRMD的紧急治疗成为可能.
- 这种向的纳米粒子系统为抑制心肌铁亡和改善心脏骤停后患者的结果提供了一个有前途的方法.
- 这种新型药物输送系统可以促进对PRMD精密治疗的进一步研究.
相关概念视频
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
75
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
75
01:26Heart Failure Drugs: Inotropic Agents
717
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
717
01:30Cardiomyopathy II: Dilated Cardiomyopathy
22
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
22
01:29Cardiomyopathy V: Interprofessional Care
33
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
33